PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
Previous Symbol
CUSIP69329Y10
Phone775-832-8500
Debt
Debt-to-Equity Ratio0.17
Current Ratio10.88
Quick Ratio10.61
Price-To-Earnings
Trailing P/E Ratio4.74
Forward P/E Ratio-5.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$320.06 million
Price / Sales1.36
Cash Flow$0.8791 per share
Price / Cash Flow3.39
Book Value$5.48 per share
Price / Book0.54
Profitability
EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins-28.41%
Return on Equity7.72%
Return on Assets5.67%
Miscellaneous
Employees87
Outstanding Shares145,980,000
Market Cap$435.01 million
OptionableOptionable
PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma declared that its Board of Directors has approved a stock repurchase plan on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 27.3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma Inc (NASDAQ:PDLI) posted its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported $0.07 EPS for the quarter, hitting the Zacks' consensus estimate of $0.07. The biotechnology company had revenue of $67.90 million for the quarter. PDL BioPharma had a negative net margin of 28.41% and a positive return on equity of 7.72%. View PDL BioPharma's Earnings History.
When is PDL BioPharma's next earnings date?
What price target have analysts set for PDLI?
1 Wall Street analysts have issued 12 month price objectives for PDL BioPharma's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's stock price to reach $3.00 in the next year. This suggests a possible upside of 0.7% from the stock's current price. View Analyst Price Targets for PDL BioPharma.
What is the consensus analysts' recommendation for PDL BioPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.
Has PDL BioPharma been receiving favorable news coverage?
Media coverage about PDLI stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. PDL BioPharma earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Rubius Therapeutics (RUBY), Spark Therapeutics (ONCE), Autolus Therapeutics (AUTL), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Gritstone Oncology (GRTS) and Cellectis (CLLS).
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- Mr. John Peter McLaughlin, CEO & Director (Age 66)
- Mr. Dominique P. Monnet, Pres (Age 57)
- Mr. Peter S. Garcia, VP & CFO (Age 56)
- Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 54)
- Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.
Who are PDL BioPharma's major shareholders?
PDL BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (8.64%), BlackRock Inc. (8.61%), Vanguard Group Inc. (7.17%), Renaissance Technologies LLC (6.28%), Connor Clark & Lunn Investment Management Ltd. (4.09%) and Brandes Investment Partners LP (2.71%). View Institutional Ownership Trends for PDL BioPharma.
Which institutional investors are selling PDL BioPharma stock?
PDLI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., AQR Capital Management LLC, Acadian Asset Management LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., Allianz Asset Management GmbH and Credit Suisse AG. View Insider Buying and Selling for PDL BioPharma.
Which institutional investors are buying PDL BioPharma stock?
PDLI stock was acquired by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Ancora Advisors LLC, Skandinaviska Enskilda Banken AB publ, Paloma Partners Management Co, JPMorgan Chase & Co. and Systematic Financial Management LP. View Insider Buying and Selling for PDL BioPharma.
How do I buy shares of PDL BioPharma?
Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDLI stock can currently be purchased for approximately $2.98.
How big of a company is PDL BioPharma?
PDL BioPharma has a market capitalization of $435.01 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe.
What is PDL BioPharma's official website?
How can I contact PDL BioPharma?
PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
